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The dearth of effective treatments for Alzheimer’s disease (AD) is one of the largest
public health issues worldwide, costing hundreds of billions of dollars per year. From
a therapeutic standpoint, research efforts to date have met with strikingly little clinical
success. One major issue is that trials begin after substantial pathological change has
occurred, and it is increasingly clear that the most effective treatment regimens will need
to be administered earlier in the disease process. In order to identify individuals within
the long preclinical phase of AD who are likely to progress to dementia, improvements
are required in biomarker development. One potential area of research that might prove
fruitful in this regard is the in vivo detection of brainstem pathology. The brainstem
is known to undergo pathological changes very early and progressively in AD. With
an updated and harmonized AD research framework, and emerging advances in
neuroimaging technology, the potential to leverage knowledge of brainstem pathology
into biomarkers for AD will be discussed.
Keywords: Alzheimer’s disease, brainstem, neuroimaging, imaging, in vivo, locus coeruleus, raphe nucleus,
biomarker
INTRODUCTION
Dementia is a global public health crisis, affecting around 47 million people worldwide and
projected to nearly triple by 2050 as the global population increases in average age (World
Health Organization, 2017). Alzheimer’s disease (AD) is the most common cause of aging-related
dementia, accounting for 60–80% of cases (Alzheimer’s Association, 2017). Even a relatively small
reduction or delay in AD incidence therefore has the potential to dramatically reduce dementia
burden (Barnes and Yaffe, 2011). Unfortunately, current AD treatments are only moderately and
transiently effective, and many promising treatments have fallen short in late-stage clinical trials
(Mehta et al., 2017). One major obstacle is the need for refined early-stage biomarkers that can
reliably predict who within the AD spectrum will develop dementia. The brainstem has long been
recognized as a site with early and significant susceptibility to AD-type neuropathological change
(Mann, 1983), but it has been difficult to access this region in vivo. Advances in non-invasive
neuroimaging techniques are beginning to allow antemortem assessment of this crucial region,
thereby opening the possibility of using early brainstem changes as AD biomarkers. This might
extend the window in which preclinical AD is detectable or, in conjunction with other biomarkers,
better define those patients most likely to experience cognitive dysfunction in the future. This
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concept will be discussed in light of the current AD research
framework and recent neuroimaging advances.
ALZHEIMER’S DISEASE PATHOLOGY
AND DIAGNOSTIC CRITERIA
The essential neuropathologic features of AD consist of
extracellular deposits of amyloid beta peptide (Aβ), and
intracellular accumulations of modified tau protein called
neurofibrillary tangles (NFTs). These pathologies are
accompanied by neuronal injury and neurodegeneration,
leading to progressive cognitive impairment and culminating
in dementia. An updated clinical staging of AD was defined
in 2011 by a joint workgroup of the National Institute on
Aging and the Alzheimer’s Association (NIA-AA) (Albert
et al., 2011; McKhann et al., 2011; Sperling et al., 2011;
Montine et al., 2012). Associated with this, the NIA-AA
published neuropathologic guidelines to score AD-associated
neuropathology as well as assess commonly appearing comorbid
pathologies (Montine et al., 2012). Importantly, the 2011
guidelines also formalized the use of imaging and cerebrospinal
fluid (CSF) biomarkers to define “preclinical AD,” wherein an
individual has abnormal AD-type pathological changes and
no or only subtle cognitive/behavioral symptoms. Validated
in vivo markers for AD-type neuropathologic change include
CSF levels of Aβ42 and phosphorylated tau, increased positron
emission tomography (PET) ligand binding for amyloid or
tau within the cortex, glucose hypometabolism as measured
by fluorodeoxyglucose PET (FDG-PET), and brain atrophy as
measured by structural magnetic resonance imaging (MRI) (Tan
et al., 2014). This biomarker-defined preclinical AD framework is
particularly useful as the preclinical phase can extend more than
a decade before the onset of clinically defined symptoms (Quiroz
et al., 2018), and therefore represents a promising window for
therapeutic intervention.
The disparity between reference to AD as a clinical
syndrome versus a neuropathologic phenomenon has led
to some confusion, however. For example, around 30% of
patients clinically diagnosed with AD do not have significant
AD neuropathology at autopsy and a similar proportion
of cognitively unimpaired patients do (Davis et al., 1999;
Neuropathology Group, 2001). In an attempt to harmonize
definitions and clarify research efforts, the NIA-AA recently
released an updated 2018 framework, building upon the 2011
biomarker-based approach in defining preclinical AD (Jack
et al., 2018; Khachaturian et al., 2018; Knopman et al., 2018;
Silverberg et al., 2018). This new system categorizes all patients
by the presence or absence of biomarker-based pathology in
three categories to generate an “ATN” profile: A for amyloid,
T for tau, and N for neurodegeneration. Additionally, there
is a cognitive staging scheme of cognitively unimpaired, mild
cognitive impairment (MCI), or dementia overlaid on the ATN
biomarker profiles (Table 1). An individual must have biomarker
group A pathology (reduced CSF Aβ42, increased amyloid PET,
etc.) to be placed on the AD spectrum, irrespective of cognitive
or other pathological changes. The framework is flexible in that it
can incorporate new ATN biomarkers as they become validated,
or entirely new biomarker categories. As will be discussed below,
neuropathological data indicate that neuroimaging-accessible
changes within the brainstem may be useful additions to the T
or N biomarker groupings.
BRAINSTEM CHANGES IN AD
Although considerable focus in the AD field has been placed
on pathological changes in cortical, hippocampal, and basal
forebrain regions, brainstem pathology has also been described
since at least the 1930s (Hannah, 1936). The brainstem is a
small and complex region, serving as a major relay center
and signal integrator for the central nervous system (CNS).
Rostro-caudally it is comprised of the midbrain, pons, and
medulla, together containing the majority of neurons belonging
to several widely projecting monoaminergic modulatory systems.
These monoamine transmitters include serotonin (5-HT) and
the catecholamines dopamine and noradrenaline (NA), the
dysfunction of which have been well-described in AD (Trillo
et al., 2013; Šimic´ et al., 2017). Early and severe AD-
associated changes occur in the major brainstem serotonergic
and noradrenergic nuclei, the dorsal raphe nucleus (DRN)
and locus coeruleus (LC), respectively, a brief summary of
which is provided below. For more in depth reading, several
comprehensive reviews have been published (Szabadi, 2013;
Trillo et al., 2013; Giorgi et al., 2017; Šimic´ et al., 2017).
The Dorsal Raphe Nucleus
The DRN is one of a cluster of serotonergic nuclei, located near
the midline in the dorsal midbrain and pons. It contains the
majority of brainstem serotonergic neurons and is comprised of
about 235,000 neurons in the adult human brain, roughly 70%
of which produce 5-HT. The DRN sends ascending projections
to regions such as the cortex, hippocampus, and striatum, as
well as descending projections to the lower brainstem and
spinal cord (Šimic´ et al., 2017). The serotonergic neurons
of the DRN undergo substantial cell loss in AD (Lyness
et al., 2003), and tangle pathology occurs early in the disease
process (Rüb et al., 2000; Grinberg et al., 2009; Braak et al.,
2011; Ehrenberg et al., 2017). Dysfunction in the serotonergic
system has been strongly implicated in the behavioral and
psychological symptoms of dementia (BPSD), such as agitation,
aggression, hallucinations, and depression (Lanctôt et al., 2001).
In particular, depressive symptoms later in life appear to be a
feature of preclinical neurodegenerative changes, even before
the onset of cognitive decline (Donovan et al., 2015; Singh-
Manoux et al., 2017). Similarly, the DRN (along with the LC)
is heavily involved in regulation of the sleep/wake cycle and
cognitively normal individuals meeting criteria for preclinical AD
have measurably worse sleep quality versus controls (Ju et al.,
2013).
The Locus Coeruleus
The LC is a long and narrow nucleus in the brainstem pons,
averaging about 14.5 mm long and up to about 2.5 mm
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TABLE 1 | Overview of NIA-AA ATN biomarker scores and cognitive staging.
Cognitive stage A T N Description of ATN profile and cognitive stage
Cognitively unimpaired (CU) − − − Normal AD biomarkers, CU
+ − − Preclinical Alzheimer’s pathologic change, CU
+ + − Preclinical AD
+ + +
+ − + Alzheimer’s and concomitant non-Alzheimer’s pathologic change, CU
− + − Non-Alzheimer’s pathologic change, CU
− − +
− + +
Mild cognitive impairment (MCI) − − − Normal AD biomarkers, MCI
+ − − Alzheimer’s pathologic change with MCI
+ + − AD with MCI (prodromal AD)
+ + +
+ − + Alzheimer’s and concomitant non-Alzheimer’s pathologic change, MCI
− + − Non-Alzheimer’s pathologic change with MCI
− − +
− + +
Dementia (DM) − − − Normal AD biomarkers, MCI
+ − − Alzheimer’s pathologic change with dementia
+ + − AD with dementia
+ + +
+ − + Alzheimer’s and concomitant non-Alzheimer’s pathologic change, DM
− + − Non-Alzheimer’s pathologic change with dementia
− − +
− + +
Only those with A biomarkers (A+) are considered to be on the AD pathological spectrum. Biomarkers for A (amyloid) include CSF Aβ42 and amyloid PET. Biomarkers for
T (tau) include CSF p-tau and tau PET. Biomarkers for N (neurodegeneration) include CSF total tau, structural changes detectable by MRI (i.e., atrophy), and FDG-PET.
Neuroimaging-detectable brainstem changes might inform the T or N categories, or potentially comprise a separate category in future iterations of the NIA-AA research
framework.
thick (Fernandes et al., 2012). It extends caudally along the
cerebral aqueduct from the level of the inferior colliculus,
ending ventrolateral to the floor of the fourth ventricle. It
consists of only about 20 to 30,000 neurons per side in
the healthy adult (German et al., 1988; Baker et al., 1989).
Despite its small size, the LC provides the majority of central
noradrenergic innervation via extensive projections throughout
the CNS and it plays important roles across behavioral, cognitive,
and physiological domains. It has also been implicated in early
BPSD changes (Matthews et al., 2002) and tangle pathology
in the LC occurs early and progressively throughout the
disease process, even prior to tangle pathology within the DRN
(Ehrenberg et al., 2017). Interestingly, the first detectable tau
pathology within the brain is in the LC, appearing even in
cognitively normal young individuals (Braak et al., 2011), and
it has been speculated that LC damage and noradrenergic
dysfunction might potentiate pathology in target regions such
as cortex and hippocampus (Heneka et al., 2010; Braun
et al., 2014; Feinstein et al., 2016). The LC undergoes severe
topographic degeneration in AD, such that areas containing
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neurons reciprocally connected to hippocampal and cortical
forebrain regions are selectively lost (Marcyniuk et al., 1986;
Lyness et al., 2003; Zarow et al., 2003; Theofilas et al., 2017),
and LC degeneration correlates with cognitive dysfunction
(Grudzien et al., 2007). It is important to note here that
the distinct but common condition known as primary age-
related tauopathy (PART) also manifests with early LC tau
pathology (Nelson et al., 2016). AD-related LC tau pathology
by definition refers only to that co-occurring with amyloid
biomarker changes (e.g., reduced CSF Aβ42, increased cortical
amyloid PET).
Although the DRN and LC are quite small, the pathology
within them occurs early, progressively, and severely, increasing
the likelihood of neuroimaging-based detection in the preclinical
phase of disease. How this might practically be achieved is the
topic of the following section.
NEUROIMAGING THE BRAINSTEM
Of the non-invasive imaging modalities available, MRI and
PET are those most commonly used in AD research (Table 2).
MRI is primarily used to rule out other causes of dementia
(e.g., stroke) and assess brain structural alterations informative
of neurodegenerative change (Kehoe et al., 2014). It can
also measure functional parameters relevant to AD pathology
such as tissue perfusion (Wolk and Detre, 2012) or blood
brain barrier (BBB) integrity (Raja et al., 2017); however,
these methods have yet to be validated for biomarker use.
PET in the AD context is employed primarily for assessment
of levels of Aβ or tau, and to measure brain glucose
hypometabolism with FDG-PET (Bao et al., 2017; Rice and
Bisdas, 2017; Villemagne et al., 2018). These measurements
are taken in relevant cortical and hippocampal regions, due
in part to logistical considerations that have limited the use
of these modalities for brainstem evaluation. The brainstem
is a small structure with substantial anatomical complexity,
requiring high resolution to visualize its component structures,
and there is little endogenous contrast to enable the easy
separation of nuclei. Additionally, significant physiological noise
is present from cardiorespiratory systems, making fine-grained
measurements difficult even with higher resolution systems (for
review see Sclocco et al., 2017). Nonetheless, refined techniques
are increasing the sensitivity of brainstem measurement, and
a recent MRI study successfully identified reductions in
dorsal midbrain volume in AD patients, corresponding to
the location of the raphe nuclei (Lee et al., 2015). The
increasing adoption of ultra-high-field (UHF) magnets for
MRI (Deistung et al., 2013) and the High-Resolution Research
Tomograph (HRRT) for PET (Schain et al., 2013), along
with improved analytical methods (Iglesias et al., 2015), are
enhancing the accessibility of these small brainstem regions to
neuroimaging.
Neuroimaging the DRN
The imaging of individual brainstem raphe nuclei poses some
challenges (Kranz et al., 2012). However, it has primarily been
achieved with the use of PET radioligands specific for 5-
HT receptors or the 5-HT transporter (Kranz et al., 2012;
Paterson et al., 2013; Schain et al., 2013; Kumar and Mann,
2014; Zhang et al., 2017). There are only two studies directly
assessing the DRN in vivo in AD spectrum changes, both
using functional MRI (fMRI). In one, reduced default mode
network connectivity of the DRN was found in patients
with AD, distinctive from changes observed in dementia with
Lewy bodies (Zhou et al., 2010). A combined PET and
fMRI study found reduced 5-HT transporter in the DRN of
patients with MCI versus controls, associated with reduced
functional connectivity between the hippocampus and DRN
(Barrett et al., 2017). In addition, neuroimaging alterations in
DRN are observable in patients with anxiety (Lanzenberger
et al., 2007; Lee et al., 2011; Johnston et al., 2015; Pillai
et al., 2018) and major depressive disorder (Lee et al., 2011;
Johnston et al., 2015; Pillai et al., 2018), indicating that
such changes might also be detectable in patients with BPSD
due to AD. Interestingly, one group has successfully used a
fusion PET/MRI system with both HRRT PET and UHF MRI
(7T) for brainstem serotonergic imaging (Cho et al., 2007).
With this system, all 5 individual raphe nuclei have been
visualized using UHF MRI and FDG-PET or 11C-DASB PET
(a radioligand for the 5-HT transporter) (Son et al., 2014).
This raises the immediate possibility of testing the hypothesis
that neurodegenerative biomarker changes may be observable
in the DRN in early stages of AD. Whether such a system
might also be able to detect other pathology (e.g., tau PET)
in the DRN remains to be seen, but such a study would
be well worth the effort. A major caveat is that the current
cost and rarity of such systems limit their use; however,
they are likely to become more common with time (Nensa
et al., 2014), especially in light of demonstrated utility in
dementia research (Dukart et al., 2011). Specific funding to
equip Alzheimer’s Disease Research Centers with such systems
would rapidly expand their use and facilitate research in this
domain.
Neuroimaging the LC
The biosynthesis of catecholamines in humans is associated with
the production of neuromelanin, putatively a mechanism to
reduce oxidative damage (Zecca et al., 2008). The noradrenergic
LC is no exception, with neuromelanin levels increasing with
age and then starting to decline around the seventh decade
of life (Mann and Yates, 1974). Conveniently, neuromelanin
has paramagnetic properties that allow regions with a high
neuromelanin content to be directly imaged with T1-weighted
or magnetization transfer weighted MRI scans on widely used
3T magnets (Sasaki et al., 2006, 2008). This neuromelanin-
sensitive MRI (NM-MRI) allows for reliable mapping of the
human LC (Keren et al., 2009, 2015; Tona et al., 2017).
Although this property is increasingly being exploited, only two
studies have applied this approach to AD patients in vivo. In
one study, a non-significant reduction in neuromelanin signal
versus controls was found, however, only 6 AD patients were
included in the study (Miyoshi et al., 2013). A subsequent
larger study of 22 AD, 38 MCI, and 26 controls reported
Frontiers in Aging Neuroscience | www.frontiersin.org 4 September 2018 | Volume 10 | Article 266
fnagi-10-00266 September 8, 2018 Time: 13:43 # 5
Braun and Van Eldik Brainstem Imaging in AD
TABLE 2 | Validated and potential neuroimaging-based biomarkers for AD-relevant pathology.
Pathology Imaging technique/sequence
Validated AD neuroimaging biomarkers1 Amyloid (A) Amyloid PET
Tau (T) Tau PET
Hypometabolism (N) FDG-PET
Atrophy (N) Structural MRI
Potential AD neuroimaging biomarkers Perfusion Arterial spin labeling, contrast-enhanced MRI
BBB integrity Contrast-enhanced MRI
Vascular reactivity Blood-oxygen-level-dependent MRI
Functional connectivity Blood-oxygen-level-dependent MRI
Neurotransmitter dysfunction Neuromelanin-sensitive MRI, MRS, PET
White matter disruption Diffusion tensor imaging
Neuroinflammation MRS, translocator protein PET∗
Synaptic dysfunction Synaptic vesicle glycoprotein 2A PET∗
Included are pathologies that have been reported in AD and techniques used to image them in vivo. The techniques listed have also been successfully applied to the
brainstem in the published literature in various contexts, with the exception of the newer PET indicators of neuroinflammation and synaptic dysfunction, marked by ∗.
MRS, magnetic resonance spectroscopy. 1Validated AD neuroimaging biomarkers are those described in the recently updated NIA-AA research framework (Jack et al.,
2018).
significantly reduced LC neuromelanin signal in both MCI and
AD patients as compared with controls, with no difference
between MCI or AD groups (Takahashi et al., 2015). This latter
finding indicates that neuronal loss might occur relatively early
in these patients, even before clinically detectable cognitive
impairment. Interestingly, a study of healthy individuals showed
that the LC neuromelanin signal positively correlates with
established proxies of neural reserve such as years of education
(Clewett et al., 2016), a finding in line with other data that
implicate the LC as a physiological substrate of cognitive
reserve (Robertson, 2013; Wilson et al., 2013). Further, another
recent study found that reduced LC neuromelanin signal
was associated with poorer memory even in healthy older
adults, particularly for emotionally negative events (Hämmerer
et al., 2018). Such findings raise the possibility that LC
neuromelanin signal may have prognostic value for older
individuals in preclinical stages of AD, well before cognitive
impairment.
In addition to NM-MRI, there have been studies examining
LC functional connectivity in healthy and clinical populations.
These studies have primarily focused on psychiatric symptoms,
showing that LC functional connectivity with certain limbic
regions is increased in patients with generalized anxiety
disorder (Meeten et al., 2016), post-traumatic stress disorder
(Steuwe et al., 2015), or those at high risk for schizophrenia
(Anticevic et al., 2014). Whether such changes are also
present in AD patients with BPSD has yet to be determined.
Additionally, PET radioligands have been developed that bind
the noradrenaline transporter (NET) (Stehouwer and Goodman,
2009; Adhikarla et al., 2016) and various adrenoceptor subtypes
(Lehto et al., 2015; Phan et al., 2017). These have even
been combined with NM-MRI, in a study demonstrating
a correlation between LC neuromelanin signal and NET
binding in certain LC projection areas in Parkinson’s disease
(Sommerauer et al., 2018). Although various studies have
found that NET density is decreased within the LC of the
AD brain (Tejani-Butt et al., 1993; Szot et al., 2000; Gulyás
et al., 2010), this has yet to be reported in AD patients
in vivo.
SUMMARY
Thanks to recent advances in neuroimaging technologies,
particularly UHF MRI, HRRT PET, and hybrid PET/MRI
systems, the capacity to measure AD-associated brainstem
pathology in vivo has reached a point where we can begin
to assess its utility. Given the neuropathological findings
described above, it is reasonable to expect alterations in these
regions in at least a subset of patients with preclinical AD
or even preclinical Alzheimer’s pathologic change (Table 1).
One of the first questions to address is whether neuroimaging-
detectable LC or DRN pathology, either alone or in some
combination with other markers, can help predict which
patients on the AD spectrum will go on to develop AD
dementia. The LC in particular seems promising in light of
the aforementioned evidence indicating its early loss in size
(Theofilas et al., 2017) and its potential role as a substrate
of cognitive reserve (Wilson et al., 2013; Clewett et al., 2016;
Hämmerer et al., 2018). Additionally, the technology to assess
its integrity in vivo is already in increasingly widespread use.
Indeed, a recent systematic review of LC NM-MRI studies
by Liu et al. (2017) identified areas where this technique
can be improved, particularly in terms of standardization
of LC signal measurements and methods of sub-regional
analysis. This latter aspect may be especially useful given the
topographic specificity of LC degeneration in AD. Additionally,
the advent of new PET radioligands for synaptic dysfunction
and neuroinflammatory change (Bao et al., 2017; Table 2)
opens new possibilities. Neuroinflammation in particular is
increasingly appreciated for its significant role in the early
etiology of AD, and various MRS-detectable metabolites have
historically been taken as indicators of neuroinflammatory
changes (Quarantelli, 2015). More recently, progress has been
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made in PET imaging of translocator protein (TSPO) as a
biomarker of activated microglia and astrocytes (Kreisl et al.,
2018).
Despite the promise, there is much to be studied before such
strategies might be employed in the clinic. The aforementioned
studies have been small in both size and number, and they
need to be expanded and replicated. A more fundamental
question of whether brainstem neuroimaging is likely to provide
benefit above and beyond other biomarkers remains and,
while it is too early to say, we believe that the potential
is worth investigating as technological advancements allow it.
Finally, whether or not neuroimaging within the LC or DRN
becomes useful clinically, the techniques outlined here afford
an opportunity to advance our understanding not only of AD
pathological progression, but other neurodegenerative diseases as
well.
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